Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Regulatory Update, Takeover Bid Withdrawal, Lending Policy Changes, Earnings Release, and Appointments - Analyst Notes on British American Tobacco, AstraZeneca, Lloyds Banking, SABmiller and Rio Tinto


News provided by

Earnings Review

03 Jun, 2014, 05:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, June 3, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Earnings Review released its analysts' notes regarding British American Tobacco (LON: BATS), AstraZeneca Plc. (LON: AZN), Lloyds Banking Group Plc. (LON: LLOY), SABmiller Plc. (LON: SAB) and Rio Tinto Plc. (LON: RIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://earnings-review.com/3264-100free.

British American Tobacco Analyst Notes
On May 29, 2014, British American Tobacco (British American Tobacco) urged the World Health Organisation (WHO) not to classify e-cigarettes as tobacco products. The Company believes that doing so would hamper the growth and development of such less risky nicotine products. The statement, released in recognition of World No Tobacco Day, called for Governments to adopt a policy of 'Tobacco Harm Reduction' as a more progressive approach to tobacco regulation. Citing a Financial Times report dated April 13, 2014, which suggested that e-cigarettes could be classified as tobacco products by the WHO, the Company said that such a move would see countries eventually restricting demand for e-cigarettes by raising taxes, curbing advertisements, and banning use in public places. "If e-cigarettes are classified as tobacco products, then the associated regulatory hurdles will mean smokers will find it harder to access less risky alternatives," said Kingsley Wheaton, Director of Corporate & Regulatory Affairs at British American Tobacco. The full analyst notes on British American Tobacco are available to download free of charge at:

http://earnings-review.com/3264-BATS-03Jun2014.pdf

AstraZeneca Plc. Analyst Notes
On May 26, 2014, AstraZeneca Plc. (AstraZeneca) informed that U.S.-based drug maker Pfizer finally withdrew its bid to acquire the Company. Pfizer, whose final takeover bid was due to expire that same day as per the UK Takeover Codes, announced that it does not intend to make an offer after AstraZeneca's Board rejected its final £55-per-share offer on May 19, 2014. Pfizer's proposal comprised of £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share. However, AstraZeneca's Board had rejected the proposal saying "it undervalues the Company and its attractive prospects." Leif Johansson, Chairman of AstraZeneca, said, "We note Pfizer's confirmation that it no longer intends to make an offer for AstraZeneca. We welcome the opportunity to continue building on the momentum we have already demonstrated as an independent company." The full analyst notes on AstraZeneca are available to download free of charge at:

http://earnings-review.com/3264-AZN-03Jun2014.pdf

Lloyds Banking Group Plc. Analyst Notes
On May 20, 2014, Lloyds Banking Group Plc. (Lloyds Banking) announced that it will limit the mortgage lending to a maximum of four times a borrower's annual earnings, in cases where the loan is worth over £500,000 on a property in UK. Lloyds Banking stated that the move was designed to address specific inflationary pressures in the London housing market where current house prices are nearly 30% above the 2007 peak, owing to supply issues. Lloyds Banking further informed that the new policy will be applied in addition to its usual affordability assessment and the Company expects the policy change to affect approximately 8% of its lending in London. Stephen Noakes, Group Director of Mortgages said, "This prudent update to our lending policies is intended to manage risks to our business and for our customers." The full analyst notes on Lloyds Banking are available to download free of charge at:

http://earnings-review.com/3264-LLOY-03Jun2014.pdf

SABmiller Plc. Analyst Notes
On May 22, 2014, SABmiller Plc. (SABmiller) reported its preliminary results for FY 2014 (period ended March 31, 2014). SABmiller registered a decline of 0.8% YoY in FY 2014 group net producer revenue to $26.7 billion, partially attributable to the political tensions in Mozambique. Weighed down by adverse foreign exchange fluctuations, SABMiller posted FY 2014 EBITDA of $6.45 billion, a growth of 1.2% YoY. The reported EBITDA, however, managed to surpass the Reuters average analyst forecast of $6.41 billion. The depreciation of key currencies against the US dollar impacted the reported EBITDA by around $400 million, said the Company. SABmiller posted adjusted earnings of $3.9 million, up 2.47% YoY, as compared to FY 2013 earnings of $3.8 million. Besides, the Company also announced the launch of new cost-cutting programme aimed at saving $500 million by FY 2018. The full analyst notes on SABmiller are available to download free of charge at:

http://earnings-review.com/3264-SAB-03Jun2014.pdf

Rio Tinto Plc. Analyst Notes
On May 29, 2014, Rio Tinto Plc. (Rio Tinto) announced the appointment of Michael L'Estrange AO as a non-executive Board Director, with effect from September 1, 2014. The Company informed that Michael L'Estrange will also join the nominations committee. Rio Tinto stated that Michael is presently the Head of College for the National Security College at the Australian National University in Canberra and a Director of the University of Notre Dame, Australia. Confirming the news, Jan du Plessis, Chairman, Rio Tinto, said, "I am delighted to welcome Michael L'Estrange to the Rio Tinto board. He is a highly-regarded individual with an impressive academic and public policy background. Michael has nearly 30 years of distinguished public service experience in Australia, and brings to our board a wealth of expertise in foreign policy, international relations and trade. His appointment further reinforces the significance of Australia to Rio Tinto's global operations." The full analyst notes on Rio Tinto are available to download free of charge at:

http://earnings-review.com/3264-RIO-03Jun2014.pdf

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] earnings-review.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] earnings-review.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] earnings-review.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Earnings Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Earnings Review in this article or report according to the procedures outlined by Earnings Review. Earnings Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Earnings Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Earnings Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Earnings Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Earnings Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Earnings Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.